menu

Loading...

SCNI Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.909

Open

0.862

VWAP

0.87

Vol

33.35K

Mkt Cap

2.95M

Low

0.840

Amount

28.90K

EV/EBITDA(TTM)

--

Total Shares

3.47M

EV

7.88M

EV/OCF(TTM)

--

P/S(TTM)

0.90

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Show More

Events Timeline

(ET)

2026-03-02

09:30:00

Scinai Immunotherapeutics Signs Amendment for PinCell Acquisition

2025-07-29 (ET)

2025-07-29

07:26:53

Scinai Immunotherapeutics' PC111 featured in peer-reviewed publication

2025-03-05 (ET)

2025-03-05

07:31:58

Scinai Immunotherapeutics announces $10M standby equity purchase agreement

2025-03-04 (ET)

2025-03-04

17:28:27

Scinai Immunotherapeutics files to sell 3.02M ADS for holders

2024-08-29 (ET)

2024-08-29

06:35:55

Scinai Immunotherapeutics regains compliance with Nasdaq

News

Newsfilter

03-02Newsfilter

PinnedScinai Immunotherapeutics Seeks €12 Million Grant for R&D Program

PRnewswire

03-02PRnewswire

Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program

PRnewswire

02-25PRnewswire

Scinai Secures Expanded Support from Israel Innovation Authority

PRnewswire

01-07PRnewswire

Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026

Newsfilter

01-07Newsfilter

Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026

Newsfilter

2025-07-29Newsfilter

Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN

Valuation Metrics

The current forward P/E ratio for Scinai Immunotherapeutics Ltd (SCNI.O) is 0.00, compared to its 5-year average forward P/E of -5.21. For a more detailed relative valuation and DCF analysis to assess Scinai Immunotherapeutics Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.21

Current PE

0.00

Overvalued PE

7.30

Undervalued PE

-17.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding SCNI

Trading Trends

People Also Watch

Frequently Asked Questions

What is Scinai Immunotherapeutics Ltd (SCNI) stock price today?

The current price of SCNI is 0.8501 USD — it has decreased -4.28

What is Scinai Immunotherapeutics Ltd (SCNI)'s business?

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

What is the price predicton of SCNI Stock?

Wall Street analysts forecast SCNI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCNI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Scinai Immunotherapeutics Ltd (SCNI)'s revenue for the last quarter?

Scinai Immunotherapeutics Ltd revenue for the last quarter amounts to 206.00K USD, decreased

What is Scinai Immunotherapeutics Ltd (SCNI)'s earnings per share (EPS) for the last quarter?

Scinai Immunotherapeutics Ltd. EPS for the last quarter amounts to -0.00 USD, decreased -100.00

How many employees does Scinai Immunotherapeutics Ltd (SCNI). have?

Scinai Immunotherapeutics Ltd (SCNI) has 31 emplpoyees as of March 03 2026.

What is Scinai Immunotherapeutics Ltd (SCNI) market cap?

Today SCNI has the market capitalization of 2.95M USD.